2-amino-4-quinazolinones as lxr nuclear receptor binding compounds
CA 2498655 A1 · Owner: Blume, Beatrix · Inventors: Hermann, Kristina; Bauer, Ulrike; Kremoser, Claus
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to 2-amino-4-oxo-quinazolines according to the general formula (1), which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds. In particular the compounds are useful in the treatment of hypercholesterolemia, obesity or other diseases associated with elevated lipoprotein (LDL) levels.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 2, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 2, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 2, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.